JP2007525527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007525527A5 JP2007525527A5 JP2007501073A JP2007501073A JP2007525527A5 JP 2007525527 A5 JP2007525527 A5 JP 2007525527A5 JP 2007501073 A JP2007501073 A JP 2007501073A JP 2007501073 A JP2007501073 A JP 2007501073A JP 2007525527 A5 JP2007525527 A5 JP 2007525527A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- carbon atoms
- compound according
- formula
- pyridyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 76
- 125000004432 carbon atom Chemical group C* 0.000 claims 64
- 125000000217 alkyl group Chemical group 0.000 claims 36
- -1 tetrahydro-3-furanyloxy group Chemical group 0.000 claims 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 17
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 8
- 101150065749 Churc1 gene Proteins 0.000 claims 8
- 102100038239 Protein Churchill Human genes 0.000 claims 8
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 7
- 125000001624 naphthyl group Chemical group 0.000 claims 7
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 4
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- 241000790917 Dioxys <bee> Species 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 4
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 2
- 150000001340 alkali metals Chemical class 0.000 claims 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims 2
- 229920001577 copolymer Chemical group 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- RSJAAVKNQYKXBN-QCDSWUKFSA-N CC(C)CN([C@@H](CCCCNC(=O)[C@H](C(C1=CC=CC=C1)C2=CC=CC=C2)NC(=O)O)COP(=O)(O)O)S(=O)(=O)C3=CC(=C(C=C3)N)F Chemical compound CC(C)CN([C@@H](CCCCNC(=O)[C@H](C(C1=CC=CC=C1)C2=CC=CC=C2)NC(=O)O)COP(=O)(O)O)S(=O)(=O)C3=CC(=C(C=C3)N)F RSJAAVKNQYKXBN-QCDSWUKFSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- KHASNRBNVBIREH-IZEXYCQBSA-N methyl n-[(2s)-1-[[(5s)-5-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-6-phosphonooxyhexyl]amino]-1-oxo-3,3-diphenylpropan-2-yl]carbamate Chemical compound C=1C=CC=CC=1C([C@H](NC(=O)OC)C(=O)NCCCC[C@@H](COP(O)(O)=O)N(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)C1=CC=CC=C1 KHASNRBNVBIREH-IZEXYCQBSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 0 C*N(C(*)**NC(C(*)N*)=O)S(C1=CC=CCC1)(=O)=O Chemical compound C*N(C(*)**NC(C(*)N*)=O)S(C1=CC=CCC1)(=O)=O 0.000 description 2
- BSZXAFXFTLXUFV-UHFFFAOYSA-N CC(c1ccccc1)c1ccccc1 Chemical compound CC(c1ccccc1)c1ccccc1 BSZXAFXFTLXUFV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2004/001440 WO2006012725A1 (en) | 2004-08-02 | 2004-08-02 | Lysine based compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007525527A JP2007525527A (ja) | 2007-09-06 |
| JP2007525527A5 true JP2007525527A5 (enExample) | 2009-08-20 |
| JP4579970B2 JP4579970B2 (ja) | 2010-11-10 |
Family
ID=35786842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501073A Expired - Fee Related JP4579970B2 (ja) | 2004-08-02 | 2004-08-02 | リシンをベースにした化合物類 |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP1773763B1 (enExample) |
| JP (1) | JP4579970B2 (enExample) |
| CN (1) | CN1942436B (enExample) |
| AT (1) | ATE417823T1 (enExample) |
| AU (2) | AU2004322123B2 (enExample) |
| BR (1) | BRPI0418651A (enExample) |
| CA (1) | CA2560071C (enExample) |
| DE (1) | DE602004018548D1 (enExample) |
| ES (2) | ES2575871T3 (enExample) |
| IL (1) | IL180958A0 (enExample) |
| MX (1) | MX2007001278A (enExample) |
| NO (1) | NO20071152L (enExample) |
| RU (1) | RU2009139259A (enExample) |
| WO (1) | WO2006012725A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7388008B2 (en) | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
| ES2575871T3 (es) | 2004-08-02 | 2016-07-01 | Ambrilia Biopharma Inc. | Composiciones farmacéuticas que comprende un compuesto a base de lisina y un agente antiviral o antirretroviral VIH |
| EP1971615B1 (en) * | 2005-11-30 | 2014-01-01 | TaiMed Biologics, Inc. | Lysme-based prodrugs of aspartyl protease inhibitors and processes for their preparation |
| JP2010502569A (ja) * | 2006-07-17 | 2010-01-28 | アンブリリア バイオファーマ インコーポレイテッド | 薬物動態学の改善方法 |
| EP2064177B1 (en) | 2006-09-21 | 2017-04-05 | TaiMed Biologics, Inc. | Protease inhibitors |
| WO2009148600A2 (en) * | 2008-06-06 | 2009-12-10 | Concert Pharmaceuticals, Inc. | Deuterated lysine-based compounds |
| EP2435037B1 (en) | 2009-05-27 | 2014-11-12 | Merck Sharp & Dohme Corp. | Hiv protease inhibitors |
| US9079834B2 (en) | 2010-10-28 | 2015-07-14 | Merck Canada Inc. | HIV protease inhibitors |
| EP2632908B1 (en) | 2010-10-29 | 2016-05-25 | Merck Canada Inc. | Sulfonamides as hiv protease inhibitors |
| US9133157B2 (en) | 2011-10-26 | 2015-09-15 | Merck Canada Inc. | HIV protease inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| CA2405151A1 (en) * | 2000-04-07 | 2001-10-18 | University Of Maryland, Baltimore | Bile acid containing prodrugs with enhanced bioavailability |
| US6617310B2 (en) * | 2000-07-19 | 2003-09-09 | Bristol-Myers Squibb Pharma Company | Phosphate esters of bis-amino acid sulfonamides containing substituted benzyl amines |
| JP2004517045A (ja) * | 2000-08-18 | 2004-06-10 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 癌およびhivの治療用ベツリン酸誘導体のプロドラッグ |
| US6506786B2 (en) * | 2001-02-13 | 2003-01-14 | Pharmacor Inc. | HIV protease inhibitors based on amino acid derivatives |
| US6632816B1 (en) * | 2002-12-23 | 2003-10-14 | Pharmacor Inc. | Aromatic derivatives as HIV aspartyl protease inhibitors |
| ES2575871T3 (es) | 2004-08-02 | 2016-07-01 | Ambrilia Biopharma Inc. | Composiciones farmacéuticas que comprende un compuesto a base de lisina y un agente antiviral o antirretroviral VIH |
-
2004
- 2004-08-02 ES ES08021798.7T patent/ES2575871T3/es not_active Expired - Lifetime
- 2004-08-02 MX MX2007001278A patent/MX2007001278A/es active IP Right Grant
- 2004-08-02 BR BRPI0418651-6A patent/BRPI0418651A/pt not_active IP Right Cessation
- 2004-08-02 WO PCT/CA2004/001440 patent/WO2006012725A1/en not_active Ceased
- 2004-08-02 EP EP04761606A patent/EP1773763B1/en not_active Expired - Lifetime
- 2004-08-02 CA CA2560071A patent/CA2560071C/en not_active Expired - Fee Related
- 2004-08-02 ES ES04761606T patent/ES2319996T3/es not_active Expired - Lifetime
- 2004-08-02 EP EP08021798.7A patent/EP2165709B1/en not_active Expired - Lifetime
- 2004-08-02 JP JP2007501073A patent/JP4579970B2/ja not_active Expired - Fee Related
- 2004-08-02 AU AU2004322123A patent/AU2004322123B2/en not_active Ceased
- 2004-08-02 AT AT04761606T patent/ATE417823T1/de not_active IP Right Cessation
- 2004-08-02 DE DE602004018548T patent/DE602004018548D1/de not_active Expired - Lifetime
- 2004-08-02 CN CN2004800427980A patent/CN1942436B/zh not_active Expired - Fee Related
-
2007
- 2007-01-25 IL IL180958A patent/IL180958A0/en unknown
- 2007-03-01 NO NO20071152A patent/NO20071152L/no not_active Application Discontinuation
-
2009
- 2009-10-23 RU RU2009139259/04A patent/RU2009139259A/ru not_active Application Discontinuation
- 2009-10-28 AU AU2009230800A patent/AU2009230800A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007525527A5 (enExample) | ||
| JP2006528700A5 (enExample) | ||
| JP2009525287A5 (enExample) | ||
| JP2006509749A5 (enExample) | ||
| JP2003503385A5 (enExample) | ||
| JP2001526218A5 (enExample) | ||
| JP2011520815A5 (enExample) | ||
| JP2008540393A5 (enExample) | ||
| JP2010514796A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| JP2003530401A5 (enExample) | ||
| JP2003523927A5 (enExample) | ||
| JP2003530318A5 (enExample) | ||
| JP2008510682A5 (enExample) | ||
| JP2010514786A5 (enExample) | ||
| JP2006500394A5 (enExample) | ||
| JP2008523098A5 (enExample) | ||
| JP2007501859A5 (enExample) | ||
| CA2386850A1 (en) | Hexahydrofuro[2,3-b]furan-3-yl-n-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor | |
| RU2009139259A (ru) | Соединения на основе лизина | |
| JP2006517201A5 (enExample) | ||
| JP2006503805A5 (enExample) | ||
| JP2002503714A5 (enExample) | ||
| JP2002526530A5 (enExample) | ||
| JP2005526773A5 (enExample) |